Davide Malavasi - COSMO Pharmaceuticals Qualified Director
| COPN Stock | CHF 62.20 0.20 0.32% |
Insider
Davide Malavasi is Qualified Director of COSMO Pharmaceuticals SA
| Age | 50 |
| Phone | 353 1 817 0370 |
| Web | https://www.cosmopharma.com |
COSMO Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0181 % which means that it generated a profit of $0.0181 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0841 %, meaning that it generated $0.0841 on every $100 dollars invested by stockholders. COSMO Pharmaceuticals' management efficiency ratios could be used to measure how well COSMO Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Kaspar Mueller | Evolva Holding SA | 60 | |
| Damian Heller | Basilea Pharmaceutica AG | 57 | |
| Dietrich Stber | Basilea Pharmaceutica AG | N/A | |
| Christian Wichert | Evolva Holding SA | N/A | |
| Eva Kalias | Santhera Pharmaceuticals Holdin | N/A | |
| Adesh Kaul | Basilea Pharmaceutica AG | 49 | |
| Gnther Metz | Santhera Pharmaceuticals Holdin | 65 | |
| Stefan Weber | Newron Pharmaceuticals SpA | 58 | |
| Marc Schrader | Santhera Pharmaceuticals Holdin | N/A | |
| David Veitch | Basilea Pharmaceutica AG | 58 | |
| Dario Eklund | Santhera Pharmaceuticals Holdin | 55 | |
| Marc MD | Basilea Pharmaceutica AG | 59 | |
| Peer Schroder | Basilea Pharmaceutica AG | N/A | |
| FCMA CGMA | Santhera Pharmaceuticals Holdin | 60 | |
| Roberto Galli | Newron Pharmaceuticals SpA | N/A | |
| Thomas Meier | Santhera Pharmaceuticals Holdin | 61 | |
| Gerhard Lobmaier | Evolva Holding SA | 54 | |
| Fabienne Gschwind | Evolva Holding SA | 50 | |
| Thomas CFA | Evolva Holding SA | N/A | |
| Laurenz Kellenberger | Basilea Pharmaceutica AG | 56 | |
| Anne Vos | Evolva Holding SA | 59 | |
Management Performance
| Return On Equity | 0.0841 | |||
| Return On Asset | 0.0181 |
COSMO Pharmaceuticals Leadership Team
Elected by the shareholders, the COSMO Pharmaceuticals' board of directors comprises two types of representatives: COSMO Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of COSMO. The board's role is to monitor COSMO Pharmaceuticals' management team and ensure that shareholders' interests are well served. COSMO Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, COSMO Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Niall Donnelly, Chief Officer | ||
| Biagio Vigano, Chief Officer | ||
| Davide Malavasi, Qualified Director | ||
| Marco Lecchi, Chief Officer | ||
| Luigi Longo, Chief Officer | ||
| Hazel Winchester, Head Relations | ||
| Giulio Evangelisti, AI Production | ||
| Alessandro LLM, CEO Director | ||
| Ngo Nhan, Head IT | ||
| Mauro Ajani, Founder Chairman |
COSMO Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is COSMO Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0841 | |||
| Return On Asset | 0.0181 | |||
| Profit Margin | 0.45 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 960.99 M | |||
| Shares Outstanding | 16.38 M | |||
| Shares Owned By Insiders | 47.28 % | |||
| Shares Owned By Institutions | 11.80 % | |||
| Price To Earning | 95.06 X | |||
| Price To Book | 2.21 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for COSMO Stock Analysis
When running COSMO Pharmaceuticals' price analysis, check to measure COSMO Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy COSMO Pharmaceuticals is operating at the current time. Most of COSMO Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of COSMO Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move COSMO Pharmaceuticals' price. Additionally, you may evaluate how the addition of COSMO Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.